Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.

Trial Details

NCT ID
NCT04617522
Phase
PHASE1
Sponsor
Gilead Sciences
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Sacituzumab Govitecan-hziy
Locations (sample)
  • Long Beach, California, United States|33.76696,-118.18923
  • Newark, Delaware, United States|39.68372,-75.74966
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Austin, Texas, United States|30.26715,-97.74306
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Histologically confirmed advanced or metastatic solid tumor that is measurable or nonmeasurable.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
  • Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute n…
  • Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →